ES2153836T3 - Composicion enmascaradora del sabor de agentes farmaceuticos amargos. - Google Patents

Composicion enmascaradora del sabor de agentes farmaceuticos amargos.

Info

Publication number
ES2153836T3
ES2153836T3 ES93305515T ES93305515T ES2153836T3 ES 2153836 T3 ES2153836 T3 ES 2153836T3 ES 93305515 T ES93305515 T ES 93305515T ES 93305515 T ES93305515 T ES 93305515T ES 2153836 T3 ES2153836 T3 ES 2153836T3
Authority
ES
Spain
Prior art keywords
flavor
amargos
pharmaceutical agents
mask composition
mask
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93305515T
Other languages
English (en)
Spanish (es)
Inventor
Joseph S Catania
Alton D Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2153836T3 publication Critical patent/ES2153836T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
ES93305515T 1992-07-30 1993-07-14 Composicion enmascaradora del sabor de agentes farmaceuticos amargos. Expired - Lifetime ES2153836T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92226292A 1992-07-30 1992-07-30

Publications (1)

Publication Number Publication Date
ES2153836T3 true ES2153836T3 (es) 2001-03-16

Family

ID=25446788

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93305515T Expired - Lifetime ES2153836T3 (es) 1992-07-30 1993-07-14 Composicion enmascaradora del sabor de agentes farmaceuticos amargos.

Country Status (29)

Country Link
US (1) US5633006A (OSRAM)
EP (1) EP0582396B1 (OSRAM)
JP (1) JP2685403B2 (OSRAM)
KR (1) KR100242399B1 (OSRAM)
CN (1) CN1030964C (OSRAM)
AT (1) ATE198421T1 (OSRAM)
AU (1) AU655892B2 (OSRAM)
CA (1) CA2101466C (OSRAM)
CZ (1) CZ285057B6 (OSRAM)
DE (1) DE69329810T2 (OSRAM)
DK (1) DK0582396T3 (OSRAM)
EG (1) EG20385A (OSRAM)
ES (1) ES2153836T3 (OSRAM)
FI (1) FI933404L (OSRAM)
GR (1) GR3035426T3 (OSRAM)
HR (1) HRP931049B1 (OSRAM)
HU (1) HU221682B1 (OSRAM)
IL (1) IL106451A (OSRAM)
MX (1) MX9304577A (OSRAM)
MY (1) MY110581A (OSRAM)
NO (1) NO308023B1 (OSRAM)
NZ (1) NZ248280A (OSRAM)
PL (1) PL174795B1 (OSRAM)
PT (1) PT582396E (OSRAM)
RU (1) RU2126257C1 (OSRAM)
SK (1) SK280194B6 (OSRAM)
TW (1) TW271400B (OSRAM)
YU (1) YU52593A (OSRAM)
ZA (1) ZA935475B (OSRAM)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
JP2977907B2 (ja) * 1994-05-06 1999-11-15 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形
JP3610418B2 (ja) * 1995-08-08 2005-01-12 カシオ計算機株式会社 液晶駆動方法及び液晶表示装置
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
GB9725219D0 (en) * 1997-11-29 1998-01-28 Cleansharp Ltd Tablets
WO2000048475A1 (fr) * 1999-02-18 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Agent masquant
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
US20030039687A1 (en) * 2001-08-01 2003-02-27 Michael Corbo Taste masking composition
JP2005501862A (ja) * 2001-08-21 2005-01-20 ファイザー・プロダクツ・インク 1回限りの投与量のアジスロマイシン
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
KR100669279B1 (ko) * 2001-12-21 2007-01-16 화이자 프로덕츠 인크. 아지트로마이신의 습식 제립 방법
BR0215193A (pt) * 2001-12-21 2004-11-16 Pfizer Prod Inc Formulações de azitromicina diretamente compressìveis
EP1478347A1 (en) * 2002-02-01 2004-11-24 Pfizer Products Inc. Dry granulated formulations of azithromycin
RU2203670C1 (ru) * 2002-02-19 2003-05-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лекарственный препарат антибактериального действия и способ его получения
EP1504761B1 (en) * 2002-04-26 2013-04-24 Fancl Corporation Difructose anhydride-containing composition and use thereof
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
AU2003214486A1 (en) * 2003-04-02 2004-10-25 Pliva-Istrazivanje I Razvoj D.O.O. Pharmaceutical compositions having reduced bitter taste
KR100503949B1 (ko) * 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
US8246996B2 (en) 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾-冻凝方法
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513139A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
BRPI0417360A (pt) 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
CN1697648B (zh) * 2003-12-04 2010-06-23 辉瑞产品公司 减少了副作用的阿奇霉素剂型
JP2007513147A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060024335A1 (en) * 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
JP2006052169A (ja) * 2004-08-12 2006-02-23 Wakoudou Kk ゾル状又はゲル状の服薬補助食品
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
NZ555501A (en) 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2016202290B2 (en) * 2005-06-17 2017-10-05 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
JP4963846B2 (ja) * 2006-03-03 2012-06-27 エルメッド エーザイ株式会社 口腔内崩壊錠及びその製造方法
ATE486593T1 (de) * 2006-03-16 2010-11-15 Novartis Ag Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ,インコーポレイテッド マクロライド系抗菌剤の調製プロセス
TWI468167B (zh) 2007-11-16 2015-01-11 威佛(國際)股份有限公司 藥學組成物
CA2711932A1 (en) * 2008-01-31 2009-08-13 Mcneil-Ppc, Inc. Edible film-strips for immediate release of active ingredients
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
JP5309262B2 (ja) 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
JP5259880B2 (ja) * 2010-09-01 2013-08-07 興和株式会社 経口剤
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013129889A2 (ko) * 2012-02-28 2013-09-06 주식회사 서울제약 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN103961368B (zh) * 2013-12-05 2017-01-04 广西大学 蒙脱石负载的氢氧化钙抗酸剂
SMT202200367T1 (it) 2014-08-28 2022-11-18 Eisai R&D Man Co Ltd Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso
CA2976325C (en) * 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR20210092202A (ko) * 2018-11-16 2021-07-23 에스에스 세야쿠 가부시키 가이샤 이부프로펜 함유 경구용 제약 제제
WO2020237172A1 (en) * 2019-05-23 2020-11-26 Xinova, LLC Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing
WO2022139863A1 (en) * 2020-12-22 2022-06-30 Solugen, Inc. Bitter masking agent
US20240188614A1 (en) * 2021-04-28 2024-06-13 Mika Tapio Reijonen Composition of the energy drink and a method of its manufacturing
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
US4127645A (en) * 1976-05-21 1978-11-28 Life Savers, Inc. Effervescent tablet and method
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
US4761274A (en) * 1986-03-27 1988-08-02 Warner-Lambert Company Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
JP2831004B2 (ja) * 1988-09-29 1998-12-02 大日本製薬株式会社 粉粒状医薬製剤
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH05139996A (ja) * 1991-11-15 1993-06-08 Lion Corp 苦味が軽減された鎮咳去痰製剤用組成物
IL104093A (en) * 1991-12-31 1999-06-20 Abbott Lab Prolamine is expected to mask the taste of drugs given orally
JPH05255120A (ja) * 1992-03-12 1993-10-05 Taisho Pharmaceut Co Ltd 苦み隠蔽製剤
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
AU4426193A (en) 1994-04-28
JP2685403B2 (ja) 1997-12-03
ZA935475B (en) 1995-01-29
EP0582396A1 (en) 1994-02-09
DE69329810T2 (de) 2001-06-21
NO308023B1 (no) 2000-07-10
HU9302213D0 (en) 1993-10-28
JPH06206824A (ja) 1994-07-26
PL299865A1 (en) 1994-02-07
ATE198421T1 (de) 2001-01-15
DK0582396T3 (da) 2001-04-09
KR100242399B1 (ko) 2000-03-02
FI933404A7 (fi) 1994-01-31
CZ285057B6 (cs) 1999-05-12
NZ248280A (en) 1995-07-26
YU52593A (sh) 1996-05-20
CA2101466A1 (en) 1994-01-31
IL106451A (en) 1998-04-05
MY110581A (en) 1998-08-29
TW271400B (OSRAM) 1996-03-01
PL174795B1 (pl) 1998-09-30
NO932736L (no) 1994-01-31
SK280194B6 (sk) 1999-09-10
CA2101466C (en) 2000-06-06
PT582396E (pt) 2001-04-30
CN1030964C (zh) 1996-02-14
GR3035426T3 (en) 2001-05-31
CN1083728A (zh) 1994-03-16
FI933404L (fi) 1994-01-31
RU2126257C1 (ru) 1999-02-20
HRP931049A2 (en) 1997-08-31
US5633006A (en) 1997-05-27
HUT64692A (en) 1994-02-28
KR940001902A (ko) 1994-02-16
AU655892B2 (en) 1995-01-12
EG20385A (en) 1999-02-28
FI933404A0 (fi) 1993-07-29
EP0582396B1 (en) 2001-01-03
SK82193A3 (en) 1994-02-02
DE69329810D1 (de) 2001-02-08
IL106451A0 (en) 1993-11-15
MX9304577A (es) 1994-02-28
CZ151893A3 (en) 1994-03-16
HU221682B1 (hu) 2002-12-28
NO932736D0 (no) 1993-07-29
HRP931049B1 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
ES2153836T3 (es) Composicion enmascaradora del sabor de agentes farmaceuticos amargos.
ES2172069T3 (es) Derivado tetrapeptidico.
GT199800126A (es) Terapia de combinacion.
ES2171416T3 (es) Remedio contra la trombocitopenia.
MX9300662A (es) Derivados fosfonooxi y carbonato de taxol
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
ES2175127T3 (es) Derivados de la quinazolina y su uso.
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ES2071986T3 (es) Enmascaramiento del sabor del ibuprofeno con revestimiento en lecho fluidificado.
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
FI930862A0 (fi) En doseringsform foer tidsvarierande moenster av laekemedeloeverlaotelse
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
MX9207374A (es) Preparacion farmaceutica que comprende una hormonade crecimiento o un derivado de la hormona de crecimiento e histidina o un derivado de histidina.
DE59310197D1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
ES2188608T3 (es) Derivado de ester trifluorometilpirroloindol carboxilico y proceso para su produccion.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
HU9501623D0 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an antidepressant drug
ES2061688T3 (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
DK0460062T3 (da) Huperzin A-analoger
ES2129397T3 (es) Derivados heteroaroilo de antibioticos beta-lactamas monociclicos.
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
CO4750755A1 (es) Mezla sinergica de un compuesto arilo o heteroarilo que inhibe la respiracion del complejo citocromo y 4-tert- butilfenilquinazolin-4il eter
ES2120962T3 (es) Composicion antivirica.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 582396

Country of ref document: ES